Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have T1DM based on the disease diagnostic criteria (World Health Organization \[WHO\] Classification).~* Have duration of T1DM ≥1 year.~* Have HbA1c ≤11 %.~* Have been administered with basal-bolus insulins or pre-mixed insulins for at least 90 days prior to screening.~* Have a body mass index (BMI) ≤35 kilograms per meter squared.~Exclusion Criteria:~* Exposure to an insulin glargine other than Lantus® within previous 30 days.~* Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study.~* Have had more than one episode of diabetic ketoacidosis or emergency room visits for uncontrolled diabetes leading to hospitalization within 6 months prior to entry into the study.~* Have known hypersensitivity or allergy to any of the study insulins (Lantus® or insulin lispro) or to excipients of the study insulins.~* Are pregnant, intend to become pregnant during the course of the study.~* Women who are breastfeeding.~* Are currently taking traditional medicine (herbal medicine or patent medicine) with known/specified content of anti-hyperglycemic effects within 3 months before screening.~* Have congestive heart failure Class III and IV.~* Have obvious clinical signs or symptoms, or laboratory evidence, of liver disease.~* Have any active cancer.~* Have a history or diagnosis of human immunodeficiency virus (HIV) infection.~* Have presence of clinically significant gastrointestinal disease.~* Have a history of renal transplantation, or are currently receiving renal dialysis.~* Are receiving chronic systemic glucocorticoid therapy at pharmacological doses.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2963016 + Insulin Lispro (Type: EXPERIMENTAL): Participants received 100 units per milliliter (U/mL) LY2963016 administered subcutaneously (SC) once daily (QD) and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
- Lantus® + Insulin Lispro (Type: ACTIVE_COMPARATOR): Participants received 100 U/mL Lantus® administered SC QD and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).